Long-term cardiovascular complications in oncologic patients after antitumor therapy (>1 year)

Oncological and cardiovascular diseases (CVD) hold a leading position among the causes of mortality in many countries of the world, including the Russian Federation [1]. In recent years, a decrease in mortality due to oncologic diseases (OD) is noted around the world thanks to early diagnostics, as well as to the development and implementation of new technologies and therapeutic treatment strategies (chemotherapy, targeted and radiation therapy). Among patients with OD who received chemotherapy and radiation therapy, CVD is one of the leading causes of poor prognosis, including lethal outcomes [2-5]. The long-term cardiotoxic effects of antitumor therapy (chemotherapy, radiation therapy) reduce the survival rate and quality of life of patients who suffer from cancer. Thus, early diagnostics and timely detection of the cardiotoxic effects that follow antitumor treatment is one of the main tasks of cardio-oncology.